Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jan 16;8(1):10.
doi: 10.1038/s41408-017-0044-5.

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia

Pablo Mozas  1 , Alfredo Rivas-Delgado  1 , Tycho Baumann  1 , Neus Villamor  2 , Valentín Ortiz-Maldonado  1 , Marta Aymerich  2 , Dolors Costa  2 , Alba Navarro  2 , Eva Giné  1   3 , Armando López-Guillermo  1   3 , Emili Montserrat  1 , Julio Delgado  4   5
Affiliations
Clinical Trial

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia

Pablo Mozas et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Overall survival for the entire patient population according to each treatment criterion individually.
a Marrow failure (P < 0.001); b short doubling time (P = 0.4); c general symptoms (P = 0.4); d lymphoid mass (P < 0.001); and e autoimmune hemolytic anemia (P = 0.06). In all plots, the gray curve represents the presence and the black curve the absence of that particular criterion. P values were adjusted using the Benjamini–Hochberg method
Fig. 2
Fig. 2. Overall survival, CLL-specific mortality and incidence of Richter's transformation according to treatment criteria.
a Overall survival according to treatment criteria, considering only patients treated because of marrow failure (MF), lymphoid mass (LM), or both (95% of the entire population). Patients who fulfilled both criteria were assigned to the MF group (P < 0.001). b CLL-specific mortality curves according to treatment criteria. Normal population mortality curves are also plotted for reference. Notice that the MF-reference mortality is slightly higher than the LM-reference mortality because this population is significantly older. c Cumulative incidence of Richter’s transformation according to treatment criteria (P = 0.20). MF patients are depicted in gray and LM patients are depicted in black
See this image and copyright information in PMC

References

    1. Dighiero G, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on chronic lymphocytic leukemia. N. Engl. J. Med. 1998;338:1506–1514. doi: 10.1056/NEJM199805213382104. - DOI - PubMed
    1. Silver RT, Sawitsky A, Rai K, Holland JF, Glidewell O. Guidelines for protocol studies in chronic lymphocytic leukemia. Am. J. Hematol. 1978;4:343–358. doi: 10.1002/ajh.2830040406. - DOI - PubMed
    1. Cheson BD, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am. J. Hematol. 1988;29:152–163. doi: 10.1002/ajh.2830290307. - DOI - PubMed
    1. Cheson BD, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997. - PubMed
    1. Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456. doi: 10.1182/blood-2007-06-093906. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources